Biolife's hemostatic portfolio contributed to Merit Medical Systems' offerings on August 13, 2025.
3 reports, 2 independent
Updated Aug 13
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 3
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Biolife's hemostatic portfolio contributed to Merit Medical Systems' offerings on August 13, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- BioLife's acquisition contributed to revenue growth for Merit Medical Systems.Sub-event
Biolife contributed its hemostatic portfolio to Merit Medical Systems' product line.1 source
Biolife acquisition expected to boost offerings, but sales dropped 6% in China.1 source
Keep exploring
The entities involved
-
BIOLIFE
Slovak company
Nothing else this week.
Coverage
Newest first; wire copies grouped- StockStory5 Insightful Analyst Questions From Merit Medical Systems’s Q2 Earnings Call Merit Medical Systems delivered a second quarter that exceeded Wall Street’s expectations, driven by strong performances i
- StockStoryMMSI Q2 Deep Dive: Execution on Cardiac and Hemostatic Growth, Reimbursement Delay for WRAPSODY Medical device company Merit Medical Systems (NASDAQ:MMSI) reported revenue ahead of Wall Street’s expe
- GuruFocus.comMerit Medical Systems Inc (MMSI) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic ... Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the f